山西省中药注射剂生产现状及发展思路分析
|
摘要
山西省是中药注射剂生产的产业大省。目前山西省共有中药注射剂生产企业18家,生产中药注射剂品种30个。对山西省中药注射剂产业的生产现状,包括优势生产企业、独家品种和优势品种,以及质量控制现状、科技研发现状等进行分析,然后结合国家相关政策分析了当前国内中药注射剂产业发展面临的挑战和问题,并针对性地提出了后续研究思路。
Shanxi is a major province of the Chinese materia medica injections(CMMIs) industry in China. There are 18 manufacturers of CMMIs in Shanxi Province, which can manufacture 30 different kinds of CMMIs. In this paper, the superior manufacturing enterprises, the exclusive and the competitive CMMIs products, as well as their quality control and scientific research situation were summarized and analyzed. In combination with the policies for CMMIs in China, the challenges as well as the further research ideas and strategies for the development of CMMIs industry in China has been put forward.
Shanxi is a major province of the Chinese materia medica injections(CMMIs) industry in China. There are 18 manufacturers of CMMIs in Shanxi Province, which can manufacture 30 different kinds of CMMIs. In this paper, the superior manufacturing enterprises, the exclusive and the competitive CMMIs products, as well as their quality control and scientific research situation were summarized and analyzed. In combination with the policies for CMMIs in China, the challenges as well as the further research ideas and strategies for the development of CMMIs industry in China has been put forward.
引文
[1]施怀生,冯俊婵.中药注射液创制考源[J].中华医史杂志,1995,25(2):107.
[2]康义瑶.中药注射剂历史回顾[N].医药经济报,2008-12-01(B03).
[3]赵燕,石上梅,王旭,等.中药注射剂国家药品标准提高及进展情况分析[J].中国药事,2017,31(8):861-876.
[4]张伯礼.中药注射剂质量控制与合理应用[J].中国食品药品监管,2012(6):64-65.
[5]国家食品药品监督管理局.WS3-B-2752-97-2014复方苦参注射液[S].2014.
[6]国家食品药品监督管理局.YBZ21642005-2009Z红花黄色素氯化钠注射液[S].2009.
[7]中华人民共和国卫生部.WS3-B-2775-97勒马回注射液[S].1997.
[8]中华人民共和国卫生部.WS3-B-3954-98桑姜感冒注射液[S].1998.
[9]中华人民共和国卫生部.WS3-B-3914-98复方蛤青注射液[S].1998.
[10]国家食品药品监督管理局.WS3-B-3825-98-2012红花注射液[S].2012.
[11]国家食品药品监督管理局.WS3-B-3707-98-2004-2012舒血宁注射液[S].2012.
[12]国家食品药品监督管理局.WS3-B-3267-98-2012冠心宁注射液[S].2012.
[13]Qu Z P,Cui J,Lee1 Y H,et al.Identification of candidate anti-cancer olecular mechanisms of Compound Kushen Injection using functional genomics[J].Oncotarget,2016,7(40):66003-66019.
[14]杨忠奇.中药注射剂再评价并非多此一举[N].健康报,2017-10-18(05).
[15]人力资源和社会保障部.关于印发国家基本医疗保险、工伤保险和生育保险药品目录(2017年版)的通知[2017-02-21].[EB/OL].http://www.Mohrss.Gov.cn/SYrlzyhshbzb/dongtaixinwen/buneiyaowen/201702/t20170223_266787.html.
[16]郝翠,刘逢芹.中药注射剂不良反应的研究进展[J].药学研究,2017,36(6):369-372.
[17]李子轲,韦娜,曹定知,等.中药注射剂不良反应及再评价概述[J].中药与临床,2012,3(2):56-59.
[2]康义瑶.中药注射剂历史回顾[N].医药经济报,2008-12-01(B03).
[3]赵燕,石上梅,王旭,等.中药注射剂国家药品标准提高及进展情况分析[J].中国药事,2017,31(8):861-876.
[4]张伯礼.中药注射剂质量控制与合理应用[J].中国食品药品监管,2012(6):64-65.
[5]国家食品药品监督管理局.WS3-B-2752-97-2014复方苦参注射液[S].2014.
[6]国家食品药品监督管理局.YBZ21642005-2009Z红花黄色素氯化钠注射液[S].2009.
[7]中华人民共和国卫生部.WS3-B-2775-97勒马回注射液[S].1997.
[8]中华人民共和国卫生部.WS3-B-3954-98桑姜感冒注射液[S].1998.
[9]中华人民共和国卫生部.WS3-B-3914-98复方蛤青注射液[S].1998.
[10]国家食品药品监督管理局.WS3-B-3825-98-2012红花注射液[S].2012.
[11]国家食品药品监督管理局.WS3-B-3707-98-2004-2012舒血宁注射液[S].2012.
[12]国家食品药品监督管理局.WS3-B-3267-98-2012冠心宁注射液[S].2012.
[13]Qu Z P,Cui J,Lee1 Y H,et al.Identification of candidate anti-cancer olecular mechanisms of Compound Kushen Injection using functional genomics[J].Oncotarget,2016,7(40):66003-66019.
[14]杨忠奇.中药注射剂再评价并非多此一举[N].健康报,2017-10-18(05).
[15]人力资源和社会保障部.关于印发国家基本医疗保险、工伤保险和生育保险药品目录(2017年版)的通知[2017-02-21].[EB/OL].http://www.Mohrss.Gov.cn/SYrlzyhshbzb/dongtaixinwen/buneiyaowen/201702/t20170223_266787.html.
[16]郝翠,刘逢芹.中药注射剂不良反应的研究进展[J].药学研究,2017,36(6):369-372.
[17]李子轲,韦娜,曹定知,等.中药注射剂不良反应及再评价概述[J].中药与临床,2012,3(2):56-59.